Northwest Biotherapeutics Opens Dedicated Leukapheresis Clinic in London
Northwest Biotherapeutics has established a dedicated leukapheresis clinic at The London Welbeck Hospital, designed to process up to four patients per day with capacity for extended hours and weekend operations as demand scales. The facility is intended to support the company’s cell therapy pipeline by bringing the collection process in-house.
Leukapheresis—the extraction of white blood cells from a patient’s blood for use in manufacturing personalized immunotherapies—has long been a logistical bottleneck in the cell therapy supply chain. By operating its own clinic, Northwest Biotherapeutics is vertically integrating a step that is typically outsourced to third-party apheresis centers, which can introduce scheduling delays and quality variability. For a company whose lead asset, DCVax-L, targets glioblastoma and depends on individualized dendritic cell manufacturing, controlling this upstream step is operationally significant. Whether the clinic’s capacity proves adequate as treatment volumes grow will be a near-term test of the build-out strategy.